2026-10-30Neutral
+13.33%24 hours changeQ3 revenue rose 36% to $5.1 billion, beating about $4.56 billion expected, as Sanofi profit share hit $2.575 billion.
read the report →← every name covered
S&P 500
REGN
Regeneron
latest move
+13.33%
2026-10-30
1 session · 2026-10-30 · avg 13.33% · largest 13.33%
Regeneron is a biotechnology company that develops and sells medicines for eye disease, allergic and inflammatory conditions, cardiovascular and metabolic disease, neurology, and oncology. Its products include EYLEA HD, Dupixent (commercialised with Sanofi), and Libtayo.